AbstractBackground and Objectives: Breast carcinoma is one of the leading causes of malignancy in females. Assessment of ER/PR and HER2/neu in breast cancer is mandatory in clinical practice. IHC for assessing hormonal receptor status is easier, safer, and has better ability to predict response to adjuvant endocrine therapy. HER2/neu overexpression is shown to have important prognostic and predictive value. The best approach to the use of immunohistochemical markers is to couple them with standard H&E histology and to use panel of markers. The purpose of the study was to assess the ER, PR & HER2/neu status and correlate with clinicopathological parameters. Methodology: 50 cases of breast carcinoma from July 2015 to June 2017 were taken for the study. H&E sections diagnosed as carcinoma were assessed for histological type and grade. Allred scoring system to score ER/PR status and ASCO/CAP guidelines for HER2/neu status were used. Histopathological grading was done according to Modified Scarf Bloom-Richardson’s method. Results: In the present study, the most common histological subtype was infiltrating ductal carcinoma (88%), and the most common immunohistochemical subtype was triple negative (40%).Most of the tumors were of histological grade II. Interpretation & conclusion: ER, PR, & HER2/neu status correlates well with histopathological grading and other clinicopathological parameters. Hence, immunohistochemical analysis should be incorporate in the routine histopathology reports and can be of great value in deciding the treatment protocols.
Keywords: Breast Carcinoma; Immunohistochemistry; Er; Pr; Her-2/Neu; Triple Negative Breast Carcinoma.
Author Information Pack
Editorial Board 
Submit article
Editor's selection process
Most popular articles
Archive
Accepted Articles
Search Articles
Email Alerts
FAQ
Contact Us